The ratio of debt to operating expenses for Rockwell Medical Inc is higher than it is for about only 5.36% of US stocks.
With a year-over-year growth in debt of -83.33%, Rockwell Medical Inc's debt growth rate surpasses merely 2.42% of about US stocks.
Rockwell Medical Inc's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -34.55%, greater than the shareholder yield of just 12.88% of stocks in our set.
Stocks that are quantitatively similar to RMTI, based on their financial statements, market capitalization, and price volatility, are LEAF, EKSO, QTRX, LC, and FLDM.
Rockwell Medical is a biopharmaceutical company targeting end-stage renal disease and chronic kidney disease with products and services for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis. The company was founded in 1995 and is based in Wixom, Michigan.
Benzinga is covering every angle of how the coronavirus affects the financial world. For daily updates, sign up for our coronavirus newsletter. Biotech stocks went on a roller coaster ride in the week ended March 20 amid the market-wide COVID-19 sell-off. Activity remained light amid the cancellation of many medical meetings. The COVID-19 treatment and vaccine development news flow was front and center, as biopharma and diagnostics companies scrambled to capitalize on the need presented by the pandemic. This news flow is likely to continue into the unfolding week, with companies already in the fray providing updates and new entrants making announcements. Related Link: 8 Biotechs With Coronavirus Vaccines In Development The following are other catalysts that could move stocks … Full stor...